CBIS Momentum Continues: Company Opens Call Center In Preparation For New Product Releases & CEO Shares His 'Impressive And Insightful' Views With Columnist

COLORADO SPRINGS, Colo., March 3, 2015 /PRNewswire/ -- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. company specializing in the development of cannabis-based medicine, today announced two important developments: It launched its toll-free call center in preparation for its multiple global product launches, and CEO Raymond C. Dabney recently shared his industry views in the Chicago HR Examiner.

In the article, Dabney answers questions from columnist Pam C. Waits about leading a company in an industry that is too new for a blueprint. Dabney discussed the goals and direction of the company, how it is helping build awareness for the effectiveness of medicinal cannabis and how it is working to bring cannabinoid-based medicines to the forefront of the healthcare community through credible research and development.

"The reader response to my Q&A with Raymond has been overwhelming," said Waits, who has been writing for Chicago Examiner since 2011. "His focus and serious approach for leading a company without an industry blueprint is impressive and insightful."

To read the Q&A in its entirety, click here: http://exm.nr/1F78MSR

"We have been overwhelmed with phone calls and emails in regards to our pre-clinical studies, state-by-state initiatives, new product releases, cannabinoid treatment education, and project partnerships," said Dabney. "This shows the general public interest and momentum toward understanding the use of cannabinoids. It is very difficult to reach out to everyone while progressing our drug development programs to meet the critical growing demand. We are very excited to report that all is moving much stronger and faster than we could have anticipated."

The new call center, Dabney said, is an opportunity for an eager public and healthcare professionals to find out more about the goals of Cannabis Science, the impressive credentials of the CBIS scientific and medical leaders and the company's current and future pre-clinical studies and upcoming product launches in the U.S. and abroad.

He said the Cannabis Science Research Foundation's "state by state initiatives" are growing quickly as the company navigates the changing laws and public perception.

"California has given us some exciting new developments as we await our final product approvals and manufacturing," Dabney said. "Our aggressive schedule has lead to exciting events we believe will greatly benefit those of interest, as our final product launch date is approaching rapidly. I believe this will be well worth the wait."

"Michigan has now matured to the point of multiplied returns; I strongly believe this will be another very important state for the company and the general public. Our New York initiatives are slowly coming to a head as we develop the required teams to handle such a large market. We also have some very special relationships in Washington DC. My frequent travel there has been a serious eye opener and has given us the ability to move in a circle of influence as never before. We also have several other state targets that are no less important from a drug development and delivery standpoint. We are constantly sorting through new opportunities to advance our programs and deliver at an accelerated rate. We look forward to hearing from the public, investors and the medical community via our new call center."

In the company's new Drug Development Initiatives, Dabney said the company's recent focus has been on continuing to develop a world-class research team and operational structures capable of meeting a growing global demand while launching pre-clinical studies in Europe, pre-clinical initiatives in the United States and other global initiatives. The company has also successfully initiated its African healthcare initiatives, targeting key issues and international concerns. As the newly appointed Vice Chair of the recently launched Constituency for Africa (CFA) Africa Healthcare Infrastructure Committee, Dabney joins retired U.S. Assistant Surgeon General Dr. Roscoe M. Moore Jr., who is CFA Interim Chair and Chair of the Africa Healthcare Infrastructure Committee.

"We are looking forward to announcing some more exciting groundbreaking news as we progress through these international landscapes favorably," Dabney said.

"Scholars, economists, industrialist and high-ranking government officials worldwide are all well aware of how important the redevelopment of this Continent is right now," Dabney said. "We have a special interest in strengthening the healthcare infrastructure to assist in the reconstruction of such an important continent. Again, I am greatly honored to be brought in so close among such great leaders, to help make a difference in Africa right now. We are rapidly determining how the Cannabis Science team can help make an immediate and long-term difference."

Dabney added that "between those activities, product launches, the publicity we've been receiving and the new toll-free line, we're firing on all cylinders. We are rapidly adding to the team as we expand our international drug development programs. We greatly appreciate your encouragement as we enjoy the growing pains as we progress forward with your support."

The company formally invites the public and healthcare professionals to call 1.888.889.0888 toll-free to speak with its team to learn more about the company and its focus to develop groundbreaking cannabinoid-based treatments.

"We thank you wholeheartedly for your interest and support of our critical-ailment drug development programs, research, education, and philanthropic initiatives," Dabney said. "We also look forward to seeing you in our Patient Access Center sharing your medical cannabinoid stories and important information with the world."

About Cannabis Science, Inc. Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches.

Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Media Contact:

VAN STONE PUBLICITY
Carrol Van Stone
[email protected] 
Tel: 304-671-0244

Cannabis Science, Inc.
Raymond C. Dabney
President & CEO, Co-Founder
[email protected]
Tel: 1.888.889.0888

Chad S. Johnson, Esq.
Director, COO & General Counsel
[email protected]
Tel: 1.888.889.0888

www.cannabisscience.com

SOURCE Cannabis Science, Inc.

Related Links

http://www.cannabisscience.com